New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Seagate Technology Holdings (NASDAQ:STX) provides data storage technology and infrastructure solutions internationally. It ...

Angus Liu breaks down phase 3 data on Enhertu from AstraZeneca and Daiichi Sankyo, while Gabrielle Masson overviews Bicara Therapeutics' investigational asset for head and neck squamous cell ...

AstraZeneca and Daiichi Sankyo trotted out Enhertu's detailed data in first-line breast cancer. Regeneron signed on a GLP-1/GIP candidate from China's Hansoh Pharma. And more. Summit Therapeutics ...

Cardiovascular benefits associated with the SGLT2 inhibitor drug canagliflozin appear to be dose-dependent, with benefits in some key clinical endpoints — including mortality — observed only ...

Sotagliflozin 400 mg provides greater improvements in HbA1c and body weight than then 200 mg dose for adults with impaired kidney function. Image: Adobe Stock Belinda Hardin, PharmD, senior ...

The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Positive results from the DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

WILMINGTON, Del. - A recent Phase III trial, DESTINY-Breast09, has demonstrated a significant improvement in progression-free survival (PFS) for patients with HER2-positive metastatic breast cancer ...